{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:54:26Z","timestamp":1781646866070,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["MUNI\/A\/1733\/2024, MUNI\/A\/1771\/2024"],"award-info":[{"award-number":["MUNI\/A\/1733\/2024, MUNI\/A\/1771\/2024"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["FNBr, 65269705, NU21-06-00363"],"award-info":[{"award-number":["FNBr, 65269705, NU21-06-00363"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malignant Hyperthermia (MH) is a rare, hereditary, life-threatening pharmacogenetic disorder. The genetic background of MH was identified only in approximately half of MH-susceptible (MHS) patients, differing between geographical areas. Variants recognised as being sufficiently functionally characterised to be used in diagnostics for MH are on the \u201cEuropean Malignant Hyperthermia Group list of diagnostic variants\u201d. However, the list may be a bit biased in the sense of rare variants in favour of better-described and published MHS cohorts. Also, the understanding of MH genetics is incomplete, with no variant identified in a significant number of cases. Aimed to investigate the clinical features, detected gene variants, and potential genotype-phenotype correlations in Slavonic patients with MH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Retrospective analysis of clinical data and molecular genetic characteristics was conducted on patients referred for possible MH during 20\u2009+\u2009years of diagnostics at the Academic Centre for Malignant Hyperthermia of Masaryk University, Brno, Czech Republic. MH susceptibility was confirmed in 94 families, containing 254 individuals. 79% of our MHS probands were diagnosed based on MH-related adverse anaesthesia complications in personal\/family history. Pathogenic\/Likely-pathogenic MH variants in the\n                      <jats:italic>RYR1<\/jats:italic>\n                      gene were detected in 48% of MHS families. In 18% of MHS patients, 14 variants of unclear significance (VUS) were detected. Three of these VUS were detected in more than one unrelated family - c.1589G&gt;A p.(Arg530His), c.1598G&gt;A p.(Arg533His), and c.6742C&gt;T p.(Arg2248Cys). We detected five families with one example of genotype-phenotype discordance. Still, in 34% of MHS probands, no variants were detected. Expanded diagnostics with neuromuscular panels or exome sequencing did not provide any additional benefit. We also presented the list of five patients with detected VUS and MH-negative In Vitro Contracture Test (IVCT).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This study presents the largest Slavonic cohort of patients investigated for risk of MH. Nearly half of the detected\n                      <jats:italic>RYR1<\/jats:italic>\n                      variants were VUS, though most appear as likely pathogenic for MH in our cohort and could be considered for a change in pathogenicity criteria. Still, over a third of MHS patients lack a confirmed genetic basis and may benefit from future advances in molecular genetic diagnostics and new scientific knowledge.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>\n                      This is a retrospective observational national cohort study reported according to STROBE guidelines (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.strobe-statement.org\/index.php?id=strobe-home\" ext-link-type=\"uri\">https:\/\/www.strobe-statement.org\/index.php?id=strobe-home<\/jats:ext-link>\n                      ). The study was registered on 05\/09\/2021 at ClinicalTrials.gov (ID: NCT05036148).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04339-w","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:05:18Z","timestamp":1774922718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Malignant Hyperthermia in Slavonic cohort \u2013 clinical and genetic findings beyond standard diagnostics"],"prefix":"10.1186","volume":"21","author":[{"given":"Martina","family":"Klincov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Z\u00eddkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"R\u00e9blov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"\u0160t\u011bp\u00e1nkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Schr\u00f6derov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Gaillyov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"B\u00f6nischov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lie","family":"Havr\u00e1nkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Tom\u00e1\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Kram\u00e1\u0159ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Fajkusov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5926","authenticated-orcid":false,"given":"Petr","family":"\u0160toura\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"4339_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13023-015-0310-1","volume":"10","author":"H Rosenberg","year":"2015","unstructured":"Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"4339_CR2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/humu.20356","volume":"27","author":"R Robinson","year":"2006","unstructured":"Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat. 2006;27(10):977\u201389.","journal-title":"Hum Mutat"},{"key":"4339_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1471-2350-10-104","volume":"10","author":"D Carpenter","year":"2009","unstructured":"Carpenter D, Ringrose C, Leo V, Morris A, Robinson RL, Halsall PJ, et al. The role of CACNA1S in predisposition to malignant hyperthermia. BMC Med Genet. 2009;10:104.","journal-title":"BMC Med Genet"},{"issue":"12","key":"4339_CR4","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1002\/humu.23635","volume":"39","author":"IT Zaharieva","year":"2018","unstructured":"Zaharieva IT, Sarkozy A, Munot P, Manzur A, O\u2019Grady G, Rendu J, et al. STAC3 variants cause a congenital myopathy with distinctive dysmorphic features and malignant hyperthermia susceptibility. Hum Mutat. 2018;39(12):1980\u201394.","journal-title":"Hum Mutat"},{"issue":"1","key":"4339_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/ALN.0000000000001878","volume":"128","author":"S Riazi","year":"2018","unstructured":"Riazi S, Kraeva N, Hopkins PM. Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept. Anesthesiology. 2018;128(1):168\u201380.","journal-title":"Anesthesiology"},{"issue":"1","key":"4339_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/ajmg.c.31887","volume":"187","author":"MA Kelly","year":"2021","unstructured":"Kelly MA, Leader JB, Wain KE, Bodian D, Oetjens MT, Ledbetter DH, et al. Leveraging population-based exome screening to impact clinical care: The evolution of variant assessment in the Geisinger MyCode research project. Am J Med Genet C Semin Med Genet. 2021;187(1):83\u201394.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"4","key":"4339_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/bja\/aex042","volume":"118","author":"A Merritt","year":"2017","unstructured":"Merritt A, Booms P, Shaw MA, Miller DM, Daly C, Bilmen JG, et al. Assessing the pathogenicity of RYR1 variants in malignant hyperthermia. Br J Anaesth. 2017;118(4):533\u201343.","journal-title":"Br J Anaesth"},{"key":"4339_CR8","unstructured":"European Malignant Hyperthermia Group. EMHG. Diagnostic MH mutations. [cited 2025 Jan 28]. Available from: https:\/\/www.emhg.org\/diagnostic-mutations"},{"issue":"5","key":"4339_CR9","first-page":"405","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med Off J Am Coll Med Genet. 2015;17(5):405\u201324.","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"4339_CR10","unstructured":"European Malignant Hyperthermia Group. EMHG. Scoring matrix for classification of genetic variants in malignant hyperthermia susceptibility. 2018 [cited 2025 Jan 28]. Available from: https:\/\/www.emhg.org\/genetic-scoring-matrix"},{"key":"4339_CR11","doi-asserted-by":"crossref","unstructured":"Johnston JJ, Dirksen RT, Girard T, Gonsalves SG, Hopkins PM, Riazi S et al. Variant Curation Expert Panel recommendations for RYR1 pathogenicity classifications in malignant hyperthermia susceptibility. Genet Med. [Internet]. 2021 July [cited 2025 Jan 26];23(7):1288\u201395. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8263483\/","DOI":"10.1038\/s41436-021-01125-w"},{"issue":"6","key":"4339_CR12","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.3390\/ijms25063489","volume":"25","author":"L Chang","year":"2024","unstructured":"Chang L, Motley R, Daly CL, Diggle CP, Hopkins PM, Shaw MA. An Association between OXPHOS-Related Gene Expression and Malignant Hyperthermia Susceptibility in Human Skeletal Muscle Biopsies. Int J Mol Sci. 2024;25(6):3489.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4339_CR13","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.bja.2018.06.028","volume":"121","author":"DM Miller","year":"2018","unstructured":"Miller DM, Daly C, Aboelsaod EM, Gardner L, Hobson SJ, Riasat K, et al. Genetic epidemiology of malignant hyperthermia in the UK. Br J Anaesth. 2018;121(4):944\u201352.","journal-title":"Br J Anaesth"},{"issue":"5","key":"4339_CR14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1213\/ANE.0b013e31828a71ff","volume":"116","author":"BW Brandom","year":"2013","unstructured":"Brandom BW, Bina S, Wong CA, Wallace T, Visoiu M, Isackson PJ, et al. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States. Anesth Analg. 2013;116(5):1078\u201386.","journal-title":"Anesth Analg"},{"key":"4339_CR15","doi-asserted-by":"crossref","unstructured":"Kraeva N, Riazi S, Loke J, Frodis W, Crossan ML, Nolan K, et al. Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population. Can J Anaesth. 2011 June;58(6):504\u201313.","DOI":"10.1007\/s12630-011-9494-6"},{"issue":"2","key":"4339_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/0310057X1504300204","volume":"43","author":"RL Gillies","year":"2015","unstructured":"Gillies RL, Bjorksten AR, Du Sart D, Hockey BM. Analysis of the entire ryanodine receptor type 1 and alpha 1 subunit of the dihydropyridine receptor (CACNA1S) coding regions for variants associated with malignant hyperthermia in Australian families. Anaesth Intensive Care. 2015;43(2):157\u201366.","journal-title":"Anaesth Intensive Care"},{"key":"4339_CR17","doi-asserted-by":"crossref","unstructured":"Gonzalez A, Girard T, Dell-Kuster S, Urwyler A, Bandschapp O. BMI and malignant hyperthermia pathogenic ryanodine receptor type 1 sequence variants in Switzerland: a retrospective cohort analysis. Eur J Anaesthesiol. 2021 Jul 1;38(7):751\u20137.","DOI":"10.1097\/EJA.0000000000001399"},{"issue":"2","key":"4339_CR18","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.bja.2022.04.029","volume":"129","author":"M Klincov\u00e1","year":"2022","unstructured":"Klincov\u00e1 M, \u0160t\u011bp\u00e1nkov\u00e1 D, Schr\u00f6derov\u00e1 I, Klabusayov\u00e1 E, O\u0161\u0165\u00e1dalov\u00e1 E, Val\u00e1\u0161kov\u00e1 I, et al. Malignant hyperthermia in Czechia and Slovakia. Br J Anaesth. 2022;129(2):e41\u20133.","journal-title":"Br J Anaesth"},{"issue":"2","key":"4339_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/bja\/86.2.283","volume":"86","author":"A Urwyler","year":"2001","unstructured":"Urwyler A, Deufel T, McCarthy T, West S, European Malignant Hyperthermia Group. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth. 2001;86(2):283\u20137.","journal-title":"Br J Anaesth"},{"issue":"4","key":"4339_CR20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/bja\/aev225","volume":"115","author":"PM Hopkins","year":"2015","unstructured":"Hopkins PM, R\u00fcffert H, Snoeck MM, Girard T, Glahn KPE, Ellis FR, et al. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth. 2015;115(4):531\u20139.","journal-title":"Br J Anaesth"},{"key":"4339_CR21","doi-asserted-by":"crossref","unstructured":"van den Bersselaar LR, Hellblom A, Gashi M, Kamsteeg EJ, Voermans NC, Jungbluth H, et al. Referral indications for malignant hyperthermia susceptibility diagnostics in patients without adverse anesthetic events in the era of next-generation sequencing. Anesthesiology. 2022 Jun 1;136(6):940\u201353.","DOI":"10.1097\/ALN.0000000000004199"},{"issue":"4","key":"4339_CR22","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/humu.20878","volume":"30","author":"S Levano","year":"2009","unstructured":"Levano S, Vukcevic M, Singer M, Matter A, Treves S, Urwyler A, et al. Increasing the number of diagnostic mutations in malignant hyperthermia. Hum Mutat. 2009;30(4):590\u20138.","journal-title":"Hum Mutat"},{"issue":"4","key":"4339_CR23","doi-asserted-by":"publisher","first-page":"E575","DOI":"10.1002\/humu.20991","volume":"30","author":"A Zullo","year":"2009","unstructured":"Zullo A, Klingler W, De Sarno C, Ferrara M, Fortunato G, Perrotta G, et al. Functional characterization of ryanodine receptor (RYR1) sequence variants using a metabolic assay in immortalized B-lymphocytes. Hum Mutat. 2009;30(4):E575\u2013590.","journal-title":"Hum Mutat"},{"issue":"2","key":"4339_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00540-021-02902-2","volume":"35","author":"YM Tsutsumi","year":"2021","unstructured":"Tsutsumi YM, Kakuta N, Kawanishi R, Tanaka K, Kanzaki R, Morio A, et al. Malignant hyperthermia in a 16-day-old infant with congenital diaphragmatic hernia: a case report. J Anesth. 2021;35(2):311\u20134.","journal-title":"J Anesth"},{"key":"4339_CR25","doi-asserted-by":"crossref","unstructured":"Ibarra MCA, Wu S, Murayama K, Minami N, Ichihara Y, Kikuchi H, et al. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology. 2006 Jun;104(6):1146\u201354.","DOI":"10.1097\/00000542-200606000-00008"},{"key":"4339_CR26","doi-asserted-by":"crossref","unstructured":"Snoeck M, van Engelen BGM, K\u00fcsters B, Lammens M, Meijer R, Molenaar JPF, et al. RYR1-related myopathies: a wide spectrum of phenotypes throughout life. Eur J Neurol. 2015 Jul;22(7):1094\u2013112.","DOI":"10.1111\/ene.12713"},{"key":"4339_CR27","doi-asserted-by":"publisher","first-page":"7638946","DOI":"10.1155\/2019\/7638946","volume":"2019","author":"A Zullo","year":"2019","unstructured":"Zullo A, Perrotta G, D\u2019Angelo R, Ruggiero L, Gravino E, Del Vecchio L, et al. RYR1 Sequence Variants in Myopathies: Expression and Functional Studies in Two Families. BioMed Res Int. 2019;2019:7638946.","journal-title":"BioMed Res Int"},{"issue":"5","key":"4339_CR28","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1399-0004.2010.01493.x","volume":"79","author":"A Tammaro","year":"2011","unstructured":"Tammaro A, Di Martino A, Bracco A, Cozzolino S, Savoia G, Andria B, et al. Novel missense mutations and unexpected multiple changes of RYR1 gene in 75 malignant hyperthermia families. Clin Genet. 2011;79(5):438\u201347.","journal-title":"Clin Genet"},{"issue":"5","key":"4339_CR29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1097\/ALN.0000000000000610","volume":"122","author":"D Fiszer","year":"2015","unstructured":"Fiszer D, Shaw MA, Fisher NA, Carr IM, Gupta PK, Watkins EJ, et al. Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness. Anesthesiology. 2015;122(5):1033\u201346.","journal-title":"Anesthesiology"},{"issue":"12","key":"4339_CR30","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1212\/01.wnl.0000188870.37076.f2","volume":"65","author":"H Jungbluth","year":"2005","unstructured":"Jungbluth H, Zhou H, Hartley L, Halliger-Keller B, Messina S, Longman C, et al. Minicore myopathy with ophthalmoplegia caused by mutations in the ryanodine receptor type 1 gene. Neurology. 2005;65(12):1930\u20135.","journal-title":"Neurology"},{"issue":"Pt 8","key":"4339_CR31","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1093\/brain\/awm096","volume":"130","author":"H Zhou","year":"2007","unstructured":"Zhou H, Jungbluth H, Sewry CA, Feng L, Bertini E, Bushby K, et al. Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies. Brain J Neurol. 2007;130(Pt 8):2024\u201336.","journal-title":"Brain J Neurol"},{"issue":"5","key":"4339_CR32","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/humu.20696","volume":"29","author":"N Monnier","year":"2008","unstructured":"Monnier N, Marty I, Faure J, Castiglioni C, Desnuelle C, Sacconi S, et al. Null mutations causing depletion of the type 1 ryanodine receptor (RYR1) are commonly associated with recessive structural congenital myopathies with cores. Hum Mutat. 2008;29(5):670\u20138.","journal-title":"Hum Mutat"},{"issue":"1","key":"4339_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40478-018-0655-5","volume":"7","author":"M Garibaldi","year":"2019","unstructured":"Garibaldi M, Rendu J, Brocard J, Lacene E, Faur\u00e9 J, Brochier G, et al. Dusty core disease\u2019 (DuCD): expanding morphological spectrum of RYR1 recessive myopathies. Acta Neuropathol Commun. 2019;7(1):3.","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"4339_CR34","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.bja.2020.07.042","volume":"125","author":"CA Ibarra Moreno","year":"2020","unstructured":"Ibarra Moreno CA, Kraeva N, Zvaritch E, Figueroa L, Rios E, Biesecker L, et al. A multi-dimensional analysis of genotype-phenotype discordance in malignant hyperthermia susceptibility. Br J Anaesth. 2020;125(6):995\u20131001.","journal-title":"Br J Anaesth"},{"issue":"5","key":"4339_CR35","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/ALN.0000000000002813","volume":"131","author":"CA Ibarra Moreno","year":"2019","unstructured":"Ibarra Moreno CA, Hu S, Kraeva N, Schuster F, Johannsen S, Rueffert H, et al. An Assessment of Penetrance and Clinical Expression of Malignant Hyperthermia in Individuals Carrying Diagnostic Ryanodine Receptor 1 Gene Mutations. Anesthesiology. 2019;131(5):983\u201391.","journal-title":"Anesthesiology"},{"issue":"2","key":"4339_CR36","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/bja\/aep108","volume":"103","author":"RL Robinson","year":"2009","unstructured":"Robinson RL, Carpenter D, Halsall PJ, Iles DE, Booms P, Steele D, et al. Epigenetic allele silencing and variable penetrance of malignant hyperthermia susceptibility. Br J Anaesth. 2009;103(2):220\u20135.","journal-title":"Br J Anaesth"},{"issue":"4","key":"4339_CR37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/sj.ejhg.5200964","volume":"11","author":"RL Robinson","year":"2003","unstructured":"Robinson RL, Anetseder MJ, Brancadoro V, van Broekhoven C, Carsana A, Censier K, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet EJHG. 2003;11(4):342\u20138.","journal-title":"Eur J Hum Genet EJHG"},{"issue":"4","key":"4339_CR38","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/bja\/aep204","volume":"103","author":"D Carpenter","year":"2009","unstructured":"Carpenter D, Robinson RL, Quinnell RJ, Ringrose C, Hogg M, Casson F, et al. Genetic variation in RYR1 and malignant hyperthermia phenotypes. Br J Anaesth. 2009;103(4):538\u201348.","journal-title":"Br J Anaesth"},{"issue":"2","key":"4339_CR39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/00000542-200208000-00010","volume":"97","author":"M Fiege","year":"2002","unstructured":"Fiege M, Wappler F, Weisshorn R, Ulrich Gerbershagen M, Steinfath M, Schulte Am Esch J. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations. Anesthesiology. 2002;97(2):345\u201350.","journal-title":"Anesthesiology"},{"key":"4339_CR40","doi-asserted-by":"crossref","unstructured":"Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand. 1997 Sep;41(8):955\u201366.","DOI":"10.1111\/j.1399-6576.1997.tb04820.x"},{"issue":"8","key":"4339_CR41","first-page":"100866","volume":"25","author":"DT Miller","year":"2023","unstructured":"Miller DT, Lee K, Abul-Husn NS, Amendola LM, Brothers K, Chung WK, et al. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med Off J Am Coll Med Genet. 2023;25(8):100866.","journal-title":"Genet Med Off J Am Coll Med Genet"},{"issue":"5","key":"4339_CR42","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1097\/ALN.0b013e3182a8a998","volume":"119","author":"JH Kim","year":"2013","unstructured":"Kim JH, Jarvik GP, Browning BL, Rajagopalan R, Gordon AS, Rieder MJ, et al. Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families. Anesthesiology. 2013;119(5):1054\u201365.","journal-title":"Anesthesiology"},{"issue":"5","key":"4339_CR43","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/ALN.0b013e3182a8a8e7","volume":"119","author":"SG Gonsalves","year":"2013","unstructured":"Gonsalves SG, Ng D, Johnston JJ, Teer JK, Stenson PD, Cooper DN, et al. Using exome data to identify malignant hyperthermia susceptibility mutations. Anesthesiology. 2013;119(5):1043\u201353.","journal-title":"Anesthesiology"},{"issue":"4","key":"4339_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/cge.12508","volume":"88","author":"M Broman","year":"2015","unstructured":"Broman M, Kleinschnitz I, Bach JE, Rost S, Islander G, M\u00fcller CR. Next-generation DNA sequencing of a Swedish malignant hyperthermia cohort. Clin Genet. 2015;88(4):381\u20135.","journal-title":"Clin Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04339-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04339-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04339-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:12:14Z","timestamp":1781644334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04339-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4339"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04339-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients or their parents gave their informed consent for the use of their clinical and laboratory data for further analysis and MH-related research including publication (approved by the Hospital Ethical Board, Brno, Czech Republic). The study was performed with the approval of the Ethical Committee of the University Hospital Brno, Jihlavsk\u00e1 20, 62500, Brno, Czech Republic (Approval Number: 20-240620\/EK; chairperson: PharmDr. \u0160\u00e1rka Koz\u00e1kov\u00e1; date of approval: 24th of June 2020, etickakomise@fnbrno.cz).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients or their parents gave their informed consent for the use of their clinical and laboratory data for further analysis and MH-related research including publication (approved by the Hospital Ethical Board, Brno, Czech Republic).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest; M.K. is a member of the EMHG Executive Committee. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}